🔗 Share this article

Given that the US continues making unprecedented revisions to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by expressing skepticism about COVID-19 vaccines in the global health crisis and has zeroed in on alleged fatalities following COVID-19 vaccination in her brief tenure at the FDA.

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials had intended to announce major changes to the childhood vaccine schedule in December, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US out of alignment with a large portion of the world with insufficient data for improved outcomes. The planned update has been postponed until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is set to present at the gathering. She was newly appointed interim head of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more like Denmark, a nation with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

So far comments, she has persisted in emphasizing on vaccination policy – usually the purview of Prasad, head of the FDA’s vaccine center – as opposed to medication approval.

Concerns Over Expertise

Dr. Høeg has no obvious background in pharmaceutical research, oversight or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and CBER since March.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in leading a large organization. She has no expertise in drug approvals.”

Former directors of CBER would “be deeply familiar with laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who headed the center have had.”

The drug center has an enormous portfolio at the agency, she stated.

“Everybody just focuses on the innovative therapies, but the generic program clears a multitude of off-brand pharmaceuticals. There’s a biosimilars division, OTC medication office and so forth, and every single one must be looked after,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant management element to the role, which oversees more than 5,000 personnel. “It is a massive administrative position, if you execute it properly,” she said.

Agency Reaction and Disputed Policies

Regarding questions about Høeg’s credentials and whether this selection represents greater collaboration among FDA leaders on immunizations, a spokesperson responded that the “concerns stem from incorrect presumptions”.

“This background is consistent with the duties of her role,” the spokesperson stated, noting the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a controversial expedited therapy clearance system that apparently troubled her former heads. “How are these therapies being chosen for this expedited pathway? Who is making the calls?” Dr. Howard questioned. “There’s a lot of secrecy going on at the FDA right now.”

Overall, he said, “the FDA looks to be trending towards more relaxed rules of pharmaceuticals, except for immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if problematic, history, some experts observe. She released a research paper using unconfirmed volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are more dangerous than they are.

Part of her “desired changes” for the new federal leadership included revising regulations for recently developed shots and ending “optional” immunizations, she said after the election on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of excluding young men from receiving Covid vaccinations.

“She is an thorough dogmatist who commences with her beliefs and tailors the evidence to retrofit the data in a highly disingenuous, fraudulent way,” Howard said.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with other skeptics, {like|